Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.52 |
| ▸ | NPY1R | P25929 | 9/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.52 |
| ▸ | NPY2R | P49146 | 5/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1119077 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL4576035 | 0.97 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL5368601 | 0.97 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL6805280 | 0.90 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30692730 | 0.89 | GNPAT (0.57) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29628174 | 0.89 | GNPAT (0.57) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL10381527 | 0.89 | GNPAT (0.57) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL23142771 | 0.88 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30051400 | 0.88 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30051461 | 0.88 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6168789-B1 | COVALENTLY MODIFIED IN ITS CATALYTIC CENTER BY A PHE-PHE-ARG-CHLOROMETHYLKETONE | ZYMOGENETICS, INC. | 2001-01-02 | — | — | US | claimed |
| US-7164002-B2 | FVIIa antagonists | GENENTECH, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20040087767-A1 | FVIIa antagonists | GENENTECH, INC. | 2004-05-06 | — | — | US | disclosed |
| US-20040067889-A1 | Stabilization of brain natriuretic peptide (BNP) in blood samples, methods and compositions related thereto | BAYER CORPORATION | 2004-04-08 | — | — | US | disclosed |
| EP-1378242-A1 | Methods and compositions for the stabilization of brain natriuretic peptide (BNP) in blood samples | BAYER CORPORATION (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030087316-A1 | Diagnostic markers of liver dysfunction | HEMOSAGA DIAGNOSTICS CORPORATION | 2003-05-08 | — | — | US | disclosed |
| WO-1994025581-A1 | MODIFIED RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR | SOUTHERN SYDNEY AREA HEALTH SERVICE (AU) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087767-A1 | FVIIa antagonists | F13B, F5, TFPI | NPY4R 1270/4885NPY1R 956/4885NPY5R 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.